Table 2.

Effect of antihypertensive drugs on cognitive decline or dementia in randomised, placebo - controlled studies

Studies	na	ΔSBP/DBP (active - placebo)	Drugs	Follow up	Outcomes
MRC	2584	−15.8/5 mmHg	BB or Diu	54 months	Non−significant effect on cognitive function
SHEP	4736	−12/4 mmHg	BB ± Diu	4.5 years	Reduction of dementia 16% (non significant)
SYST-EUR	2418	−8.3/3.8 mmHg	CCB ± ACEI ± Diu	2 years	Reduction of dementia 50% (0 to 76%)
SYST-EUR 2 (open follow up)	2902	–7/3.2 mmHg	CCB ± ACEI ± Diu ± others	4 years	Reduction of dementia 55% (24%–73%)
PROGRESS	6105	−9/4 mmHg	ACEI ± Diu	4 years	Reduction of cognitive decline 19% (4%–32%) Reduction of dementia with recurrent stroke: 34% (3%–55%)
HOPE	9297	−3.8/2.8 mmHg	ACEI	4.5 years	Reduction of cognitive decline related to stroke 41% (6%–63%)
SCOPE	4964	−3.2/1.6 mmHg	ARB ± Diu	3.7 years	Reduction of dementia 7% (non significant)

^an = numbers of subjects at inclusion.

Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta blockers; CCB, calcium channel blockers; Diu, diuretics.